

Ref. No: FOI2278
Date: 09/01/2026
Subject: Intra-vitreous injections or implants

REQUEST

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2025:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis
- Ranibizumab - Biosimilar

2. Please provide the number of injections/implants administered within the four-month period from September to December 2025 with the below treatments for noninfectious Uveitis (NIU) only

- Dexamethasone
- Fluocinolone acetonide

RESPONSE

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from September to December 2025:

- Aflibercept – 1,167
- Bevacizumab - 0
- Brolucizumab - <5
- Dexamethasone - 51
- Faricimab - 977
- Fluocinolone acetonide - 0
- Ranibizumab – Lucentis - 0
- Ranibizumab – Biosimilar - 339

2. Unable to answer as we do not hold information on specific indications.